CompletedNot Applicable

Eplerenone for the Treatment of Central Serous Chorioretinopathy

United States108 participantsStarted 2013-10

Plain-language summary

To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Acute- first episode or symptoms less than one month prior to presentation
✓. Chronic- previously documented sub-foveal fluid, any prior treatment, symptoms for over 3 months, or \<50% reduction in fluid thickness on OCT after 3 months.

Mean Change in Maximal Subretinal Fluid Height Based on Spectral Domain Optical Coherence Tomography (OCT) Measurement.

Timeframe: Baseline and 2 months

NCT IDNCT01990677

SponsorWills Eye

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-03

Results submitted2017-04-12